Adhera Therapeutics Inc (ATRX) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adhera Therapeutics Inc   (ATRX)

Adhera Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Adhera Therapeutics Inc in the second quarter 2023?
Due to the lack of equity, it was not possible to calculate Adhera Therapeutics Inc 's return on equity (ROE) in its second quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change 173.74 % - - - -
Net Income (TTM) in Millions -3 -3 -2 -6 -4
Return On Equity (TTM) - - - - -
ATRX's Total Ranking # # # # #
Equity (TTM) in Millions -23 -23 -22 -22 -20
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ATRX Management Effectiveness >> ATRX's 5 Years Annual ROE >> Compare ATRX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ATRX Annual Return On Equity (Dec 31 2022)
2022



Total Equity in Millions -22 0 0 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -2 0 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to ATRX Management Effectiveness >> ATRX's 5 Years Annual ROE >> Compare ATRX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ATRX's' Return on Equity at Yahoo Finance
ATRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ATRX's Competitors
Subscribers only: Roe for Adhera Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for ATRX's Customers




Companies with similar Return On Equity at Jun 30 2023, within Healthcare Sector ROE
Denali Therapeutics Inc   32.16 %
Arcturus Therapeutics Holdings Inc   31.17 %
Semler Scientific inc   30.26 %
Escalon Medical Corp   28.97 %
Bruker Corporation  28.47 %
Chemed Corporation  27.03 %
Zynex inc   26.71 %
Gilead Sciences Inc   25.83 %
Bristol myers Squibb Company  24.97 %
Resmed Inc   24.17 %
Carlisle Companies Incorporated  23.86 %
Vertex Pharmaceuticals Inc  23.68 %
Viskase Holdings inc   23.34 %
Point Biopharma Global Inc   22.69 %
Edwards Lifesciences Corporation  22.63 %
Encompass Health Corporation  22.19 %
Pfizer Inc  22.11 %
Iradimed Corporation  21.22 %
Agilent Technologies inc   20.65 %
Ufp Technologies Inc   20.45 %
Dynavax Technologies Corporation  19.86 %
Maravai Lifesciences Holdings Inc   19.61 %
Biogen Inc   19.60 %
Corcept Therapeutics Inc  19.57 %
Patterson Companies Inc   19.52 %
West Pharmaceutical Services Inc   19.43 %
Iqvia Holdings Inc   18.86 %
Amphastar Pharmaceuticals Inc   18.78 %
Regeneron Pharmaceuticals Inc   18.77 %
Ensign Group Inc  18.73 %

Date modified: 2026-09-08T15:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.